• All sections
  • C - Chemistrymetallurgy
  • C07D - Heterocyclic compounds
  • C07D 211/34 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Patent holdings for IPC class C07D 211/34

Total number of patents in this class: 448

10-year publication summary

31
21
27
33
29
32
37
22
27
12
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026

Principal owners for this class

Owner
All patents
This class
Incyte Corporation
1072
14
Incyte Holdings Corporation
626
12
Commave Therapeutics SA
18
12
Novartis AG
10279
11
Biogen MA Inc.
937
11
Nocion Therapeutics, Inc.
50
9
Boehringer Ingelheim International GmbH
4502
8
Praxis Precision Medicines, Inc.
231
8
ReNAgade Therapeutics Management Inc.
58
8
Massachusetts Institute of Technology
10237
7
The General Hospital Corporation
4855
7
The Broad Institute, Inc.
1968
7
AstraZeneca AB
2815
6
Takeda Pharmaceutical Company Limited
2713
6
Guangzhou Innocare Pharma Tech Co., Ltd.
13
6
Astellas Pharma Inc.
1042
5
ChemoCentryx, Inc.
361
5
H. Lee Moffitt Cancer Center and Research Institute, Inc.
1017
5
Telo Therapeutics, Inc.
7
5
The Regents of the University of Michigan
4970
4
Other owners 292